Key Takeaways
- FDA Breakthrough Therapy designation granted for olomorasib + pembrolizumab in first-line KRAS G12C-mutant advanced NSCLC with PD-L1 ≥ 50%.
- Clinical validation from Phase 1/2 LOXO-RAS-20001 and Phase 3 SUNRAY-01 trials supports expedited development.
- Upcoming data spotlight: Updated results to be presented at the 2025 IASLC World Conference on Lung Cancer in Barcelona.
Regulatory Milestone Positions Lilly in the KRAS Race
The U.S. FDA has granted Breakthrough Therapy designation to olomorasib, Eli Lilly’s highly selective second-generation KRAS G12C inhibitor, when combined with Merck’s KEYTRUDA® (pembrolizumab). This recognition underscores olomorasib’s potential to significantly improve outcomes for patients with newly diagnosed, unresectable or metastatic NSCLC harboring a KRAS G12C mutation—a historically difficult-to-target oncogenic driver.
Clinical Evidence Driving Acceleration
The designation builds on encouraging results from LOXO-RAS-20001 (Phase 1/2) and the SUNRAY-01 (Phase 3) trials. Preliminary data indicate strong efficacy, tolerability, and potential central nervous system (CNS) activity, a key differentiator in treating metastatic lung cancers. Lilly will share updated efficacy and safety results at the IASLC 2025 World Conference on Lung Cancer, offering the oncology community a first look at longer follow-up data and expanded patient cohorts.
A Pivotal Step in Lilly’s Oncology Strategy
For Lilly, olomorasib represents a strategic advance into the KRAS inhibitor class, a field with significant competitive activity and unmet patient needs. By developing olomorasib both as a monotherapy and in immunotherapy-based combinations, Lilly is positioning itself to compete in the first-line NSCLC market, where durable responses and tolerability remain critical challenges.
About Olomorasib
Olomorasib (LY3537982) is an oral, potent, and selective second-generation KRAS G12C inhibitor designed for high target occupancy with reduced toxicity, enabling safer use in combination regimens. KRAS G12C mutations are found in approximately 13% of NSCLC patients and up to 3% of other solid tumors, representing a major unmet clinical need.
About Lilly
Eli Lilly and Company (NYSE: LLY) is a global leader in biopharmaceutical innovation, advancing transformative medicines across oncology, diabetes, obesity, Alzheimer’s disease, and immunology. With nearly 150 years of scientific discovery, Lilly is committed to harnessing cutting-edge biotechnology, chemistry, and genetic medicine to address some of the world’s most challenging health conditions.
By
